Abstract Liver failure is one of the main risks of death worldwide, and it originates from repetitive injuries and inflammations of liver tissues, which finally leads to the liver cirrhosis or cancer. Currently, liver transplantation is the only effective treatment for the liver diseases although it has a limitation due to donor scarcity. Alternatively, cell therapy to regenerate and reconstruct the damaged liver has been suggested to overcome the current limitation of liver disease cures. Several transplantable cell types could be utilized for recovering liver functions in injured liver, including bone marrow cells, mesenchymal stem cells, hematopoietic stem cells, macrophages, and stem cell-derived hepatocytes. Furthermore, paracrine effects of transplanted cells have been suggested as a new paradigm for liver disease cures, and this application would be a new strategy to cure liver failures. Therefore, here we reviewed the current status and challenges of therapy using stem cells for liver disease treatments.
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Introduction
The liver is one of the important organ that has diverse functions such as digestion, metabolism, detoxification, storage, production, and so on [1, 2] . Since the liver is responsible for many vital roles in maintaining life, liver failure is closely related to the patient mortality.
The liver has strong regenerative capacity, however, repetitive damages in the liver can cause malfunction of hepatic repair. Virus infections, alcohol abuse, drug-induced hepatotoxicity, and many other factors induce damage of liver cells by mediating inflammations and tissue injuries [3, 4] . When the liver is exposed to these harmful conditions persistently, the regenerative capacity of the liver is progressively lost and fibrosis occurs, then, the liver cirrhosis develops which there is irreversible scarring of the liver. Currently, liver transplantation is the only reliable and effective treatment for this irreversible damage of the liver, however, this approach is hampered by the limited supply of donor and complications of long-term immunosuppression [5] .
To overcome donor scarcity of liver transplantation, researchers have begun to develop the cell transplantation strategy using stem cell and stem cell-derived hepatocytes [6] [7] [8] . Many research groups have demonstrated the therapeutic potentials of various cell types such as bone marrow cells, mesenchymal stem cells, hematopoietic stem cells, macrophages, and in vitro differentiated hepatocytes [9] [10] [11] [12] . Although each cell type has eminent strengths and weak points to be improved, the transplanted cells have therapeutic effects on the improving host liver functions and inducing liver regeneration by both replacing host tissues and improving host environment [13, 14] . Interestingly, it is also believed that the beneficial effects of transplanted cells for liver disease cure come from the paracrine effects by secreted molecules from transplanted cells [14, 15] . Therefore, unravelling the action of stem cells for liver regeneration would be an invaluable study to develop the liver disease cure.
In this review, we focus on the current strategy to overcome liver failure and the role of stem cells and its therapeutic use.
The liver
Liver architecture involves main five components: vascular system, hepatocytes, hepatic sinusoidal cells, biliary system, and stroma [2] . Among the various components of the liver, cell types that are responsible for the main functions of the liver are hepatocytes, which perform most of metabolic, synthetic, and detoxifying functions and occupies the majority of total liver mass. The remaining parts of the liver are composed of the non-parenchymal cells (NPCs) such as sinusoidal endothelial cells, hepatic stellate cells (HSCs), kupffer cells, cholangiocytes, and the others [16] . Hepatocytes have well-organized polarity with the adjacent NPCs and the maintenance of structural polarity directly contribute to the functional polarity [17] .
The liver is the primary site of detoxification and plays a pivotal role as the safety guard to defense and detoxify any toxic and harmful materials such as metabolic wastes, drugs, alcohol and chemicals. The liver also processes the nutrient absorption and secretes a variety of proteins such as the plasma protein, albumin, glucose, cholesterol, and many specialized proteins. Especially, the liver secretes bile, which helps the digestion and absorption of fats. Further, the liver functions as a storage reservoir of glucose and regulates the ammonia level in the body thereby maintaining homeostasis.
Liver regeneration
Damages such as viral infection, chemical toxicity and metabolic overload cause hepatic cell death, and it activates the series of molecular events to repair and regenerate damaged tissue. Regeneration process is controlled by the action of various cytokines and growth factors [18] , and the factors involved in the liver regeneration are well studied in animal model of partial hepatectomy (PH), a surgical method to remove the injured liver (Table 1) . Upon PH, kupffer cells activate tumor necrosis factor-a (TNF-a) [19, 20] , and this cellular event is mediated by the induction of NF-kB, and functions as an important regulator of the early stage of regeneration. Simultaneously, kupffer cells upregulate the expression of interleukin-6 (IL-6) by the action of secreted TNF-a [21, 22] . IL-6 exerts its function through the downstream signaling pathways and mediates mitotic activation and recovery of liver tissue [23, 24] . Furthermore, hepatocyte growth factor (HGF) is dramatically increased after PH, and enhances hepatocyte proliferation and regeneration [25, 26] . Other growth factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor (IGF) are involved in liver regeneration [27] [28] [29] [30] [31] [32] [33] .
During liver regeneration process, many signaling cascades are also involved. b-catenin is predominantly stabilized in hepatocytes and contributes to proliferation and regeneration [34, 35] . The main components of Notch pathways are upregulated after PH, and genetic study revealed that the Notch pathway is involved in the regeneration of injured tissue and liver vasculature [36, 37] . Transforming growth factor-beta 1 (TGF-b1) expression is transiently peaked after PH and genetic study shows that TGF-b1 interrupts hepatocyte proliferation during regeneration phase [38, 39] . Activation of downstream molecule, SMAD mechanistically explains the role of TGF-b1 in regeneration. Considering the working mechanism of TGFb1, it might be involved in the termination of liver regeneration [40, 41] .
Liver fibrosis
Although the liver is a remarkable organ playing diverse roles with excellent regenerative ability [6] , subsequent and repeated damages on liver tissue cause severe inflammations and attenuate the ability to regenerate and repair the damaged parts of the liver. In other words, hepatic tissue proceeds to the next stage, called liver fibrosis. When the fibrosis get worse, liver cirrhosis occurs which accelerate hepatocellular dysfunction and liver failure.
Liver fibrosis is characterized by altering the hepatic architecture caused by aberrant accumulation of extracellular matrix (ECM) proteins [42, 43] . The main reason of the accumulation of ECM is HSCs. Continuous damages to the liver such as inflammation result in the activation of quiescent HSCs, and increase the expression of ECM proteins. Excessive ECM interrupts with normal physiology and function of the liver. Among various cytokines involved in fibrogenesis, TGF-b1 plays an important role in the progression of fibrosis. TGF-b1 stimulates the conversion of HSC into fibroblast-like cell and mediates abundant fibrillar collagen deposition [44, 45] . Plateletderived growth factor-B (PDGF-B) is also overexpressed during hepatic fibrogenesis and functions as a mitogen for HSCs [46] . Angiotensin II which raises the blood pressure, induces hepatic inflammation and mediates the serial action of fibrogenesis by acting through angiotensin II receptor type 1 receptors [47, 48] . One of the major adipokines, Leptin is also known to be required in hepatic fibrogenesis and ECM remodeling [49] . Fibrotic ECM is mainly regulated by the expression level of matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMP) [50, 51] . When TIMP-1 is overexpressed by activated HSCs, ECM degradation is strongly inhibited and the liver becomes stiffer. If liver fibrosis is continuously progressing, it leads to hepatic cirrhosis or liver cancer, which lowers the quality of life (Fig. 1 ).
Source of transplantable cells for liver failure
To treat severe liver failure, liver transplantation is the only effective cure for the patients. However, it is limited by the lack of healthy organ donation [13] . Therefore, studies on cell therapy and cell transplantation have developed to overcome the facing limitation. Among the transplantable cell sources, primary adult human hepatocytes (PHHs) acquired from donors could provide a great source for transplantation. However, the PHHs are not suitable for transplantation due to prolonged ischemia and [52, 53] , and the oval cells are considered as a good transplantable source for liver disease treatment because of their bi-potentiality. However, the numbers of the oval cells in the liver are very limited and technical development for the isolation, purification, and expansion of the oval cells is a challenging task [54, 55] . Therefore, stem cells are proposed as a new source of cell transplantation for liver disease cure because of their proliferation and pluripotency (Table 2 ).
Stem cell therapy for liver diseases
To improve the prognosis of liver failure, many researchers have studied on the therapeutic potential of stem cell transplantation (Table 3) .
Bone marrow cells (BMCs) have been studied for a long time to treat liver diseases [56] [57] [58] . BMCs are multipotent cells which have the differentiation potential into liver cells and secrete beneficial molecules such as matrix metalloproteinase to reduce liver fibrosis [9, 59, 60] . Although therapeutic effect of BMCs is promising, cell preparation step requires quite invasive procedure and the complex and heterogenous components of BMCs need to be identified.
Mesenchymal stem cells (MSCs) are one of the great cell sources for alternative therapeutic options to treat liver disease [10, 61, 62] . MSCs have attractive features such as proliferation ability, differentiation capability, and immune-evasive property. Many different types of MSCs have been proven to be effective transplantable sources in liver failures by differentiating into hepatocytes, and there are several reports about therapeutic effects of MSCs from various stem cell niches. MSCs taken from bone marrow showed improving liver functions when injected into patients suffered from different types of liver disease such as hepatitis and alcohol abuse [63] [64] [65] [66] [67] [68] . Liver-derived MSCs also could be a novel therapeutic source for liver disease because they are able to differentiate into mature hepatocytes and contribute to liver regeneration in acute liver injury model [69] [70] [71] . Amniotic fluid-derived MSCs and its hepatic progenitor cells showed recovering liver injuries in the mouse model of acute hepatic failure [72] . MSCs collected from other sources such as umbilical cord or cord blood also exhibited clinical therapeutic effect in patients with liver cirrhosis [73] . Recently, transplantation of hepatic cell sheets derived from MSCs also accelerated liver regeneration in mouse models, raising the possibility of an alternative therapy of liver transplantation [74, 75] . MSCs are an excellent therapeutic candidate that are free from ethical concerns and could be isolated from various sources [76, 77] . However, major hurdle for use of MSCs in clinical applications is variability in cell quality depending on donors, sources, and preparation techniques [78] .
Other cell types also have been considered as a transplantable source for liver disease treatment. Administration of hematopoietic stem cells into patients with chronic liver disease also showed clinical and biochemical improvement of the patients [79, 80] . However, although hepatocyte differentiation potential of hematopoietic stem cells reported, exact therapeutic mechanism is still controversial [11, 81] . Injection of macrophages derived from bone marrow also improves clinically relevant parameters in liver fibrosis animal model [12] . Interestingly, in the study of transgenic mouse model (CD11b-DTR) that could selectively deplete macrophage, it was found that macrophage has opposing effects depending on the stage of progression, and beneficial effect of macrophage was prominent in recovery stage not injury stage [82] .
Otherwise, human pluripotent stem cells (PSCs) including embryonic stem cells (ESCs) and induced [93] hpUCMSC secretome -500 lg ip CCl4-injured BALB/c mice 6 weeks 0.5 ml/kg (ip, 6 weeks, twice a week) [93] pluripotent stem cells (iPSCs) are also valuable sources in tissue regeneration [83] . Since the human PSCs could proliferate indefinitely and differentiate into all functional cell types in our body, they could provide stable transplantable hepatocytes for liver disease cure [84, 85] . In that reason, recently, many research groups have demonstrated that hepatocyte-like cells derived from human PSCs successfully engrafted into the liver tissue and contributed to recovery of injured liver [86] [87] [88] [89] . Upon transplantation of human PSC-derived hepatocytes, they could integrate into the host liver and rescue the liver disease in the animal model. However, the cell therapy using human PSCderived hepatocytes still have limitations including risk of teratoma formation [90] , and the maturity of differentiated hepatocytes from PSCs is also still on issue [91, 92] . More recently, many evidences indicate that transplanted cells could integrate into the host liver, as well as the cells could influence the host regenerative system by paracrine effects [72, 88, 93] . These potent paracrine effects of stem cell-derived factors could provide ''cellfree'' therapeutic options in liver disease cure.
Stem cell-derived factors for liver disease cure
Many researches indicate that stem cell therapy using MSCs shows significant improvements in liver functions [14, 94, 95] . However, other studies questioned beneficial effects of MSC transplantation [96] [97] [98] . Depending on methodological differences including cell types, injection routes, and phase of liver fibrosis, it is difficult to interpret the discrepancy observed in previous studies. Therefore, soluble factors secreted by MSCs have been suggested to play an important role in liver regeneration [14] . In the context of beneficial paracrine effects of MSCs, it has been demonstrated that bone marrow-derived MSC conditioned medium (CM) showed anti-apoptotic and pro-mitotic effects on cultured hepatocytes by increasing hepatocyte protective cytokine IL-6 [99, 100] . Moreover, systemic injection of MSC-CM could inhibit hepatic cell death and improve liver regeneration in D-galactosamine-induced acute liver injury model [101] . Specific molecules responsible for MSC-CM therapy are expected to be VEGF, HGF, IGFBP, IL-6, and other cytokines related with liver regeneration. In fact, CM obtained from MSC marker expressing-human liver stem cells isolated from human cryopreserved normal hepatocytes contains many paracrine factors such as IL-10, VEGF, IL-8, HGF, IGF-1, and IL-6 [102] . Therefore, administration of MSC-CM induces expression of genes relevant for hepatocyte proliferation, anti-inflammatory responses, and pro-angiogenic factors after partial hepatectomy [103] . Further, human umbilical cord-derived matrix stem cells (hUCMSCs) significantly increased the survival of acute liver failure in mice by stimulating endogenous liver regeneration [104] . Study from co-culture with hUCMSCs indicates that paracrine effects play key roles in stimulation of endogenous liver regeneration. MSC mesenchymal stem cell, HPL hepatic progenitor-like, BM bone marrow, iPSC induced pluripotent stem cell, ESC embryonic stem cell, UCMSC umbilical cord-derived MSC, hpUCMSC UCMSC-derived hepatocyte-like cell, ip Intraperitoneal injection, iv intravenous injection,
In addition to liver regeneration by stem cell-derived factors, the MSC exosomes have also been described to have anti-fibrotic effects by inhibiting TGF-b1/Smad signaling pathway and suppressing epithelial mesenchymal transition. [105] . Exosomes are considered as intracellular compartments that manage protein wastes, however, recent studies indicate that exosome contains various microRNAs, mRNAs and proteins, which are involved in intracellular communication. Exosomes derived from human menstrual blood-derived stem cell expressed cytokines such as IL-6, IL-8, insulin-like growth factor-binding protein-6 and improved survival rates and recovered liver functions when the exosomes were injected in D-galactosamine and lipopolysaccharide induced mouse model [106] . Since exosomes and are known to modulate progression of hepatic fibrosis, the exact mode of actions and responsible molecules need to be explained in more detail [107] [108] [109] .
However, the secretome contains various factors including molecules that may result negative effect on liver regeneration. Therefore, to discover key therapeutic factors in secretome from stem cells and their differentiated hepatocyte-like cells, proteomic analysis was performed by researchers and several identified putative molecules were reported (Table 4) . Among various candidates, milk fat globule-epidermal growth factor 8 (MFG-E8) was identified as a key molecule for rescuing liver fibrosis [93] . In fact, injection of human MFG-E8 instead of whole secretome showed comparable anti-fibrotic effects to the whole secretomes [93] . Further, MFG-E8 truly decreased the ECM accumulation in the liver fibrosis model and inactivated HSCs by inhibiting TGF-b signaling pathways, one of the major mechanistic regulators of liver fibrosis [93] .
Therapeutic use of stem cells in paracrine manner is also well documented in other disease models. Neurodegenerative disease such as Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, and many others, are characterized by structural and functional destruction of neurons [110] [111] [112] [113] . Recent studies on stem cell therapy indicate that the beneficial effect mainly rely on auto/paracrine activities. A variety of cytokines and growth factors that secreted by injected stem cells regulate rearrangement of the microenvironment, and mediate neural protection and repair processes. Similar approach confirmed the phenotypical improvement of cardiovascular disease such as myocardial infarction [114, 115] . In mice model of ischemia, MSC secretome mediated neovascularization and induced myocardial protection by preventing apoptosis, inflammation, and fibrosis. As mentioned above, finding out the therapeutic molecules secreted from stem cells is the current trend in research and clinical fields (Fig. 2) . Therefore, further research would be promising to find out the other key molecules in secretome and its downstream signaling pathways that are also involved in therapeutic improvements in liver failure.
Conclusion and future perspectives
As the liver is essential for maintaining life, liver regeneration should be finely coordinated. Many efforts have been made to find out the best way for the treatment of liver diseases. Up to date, organ transplantation is the widely accepted option to treat the patient with liver failures or liver diseases. However, there are several limitations such as an excessively deficient number of organ donation and possible complications that include immune rejection, risk of infection, and graft failure. From these circumstances, therapeutic use of stem cells has emerged as an alternative treatment for the liver diseases.
Transplantation of stem cell such as BMCs, MSCs, hematopoietic stem cells, macrophages truly shows beneficial effects in the patient with liver failure. Therapeutic improvement after stem cell treatment is mainly mediated by replacing damaged tissues and secreting soluble factors. BMCs are multipotent progenitors that could attenuate liver fibrosis. MSCs are the most frequently studied cell types that have many advantages on the clinical applications including differentiation capabilities, regenerative potential, immune modulation, and paracrine activity. Hematopoietic stem cells are versatile cells harboring hepatocyte differentiation which have much higher potential to differentiate. Since human PSCs could proliferate indefinitely without losing their characteristics, it is feasible preparing large quantities of cells needed for treatment. When differentiation technique is combined with reprogramming strategy, also known as induced pluripotent stem cell generation, it is possible to generate transplantable liver cells without the concern for immune rejection [116] . Cellular approaches that are mentioned above, could integrate with other techniques such as gene therapy, bioartificial liver devices, or bioengineered organs to improve therapeutic applications [117] . However, there are still challenges to be solved. In vitro differentiated hepatocytes have similar properties of primary hepatocytes but they are considered to be fetal-like cells in terms of maturation [118] . For therapeutic applications, upregulating the levels of albumin production, urea production, cytochrome P450 activity, and mitochondrial function need to be achieved. Recently, paracrine effects of transplanted cells are actively under investigations. For example, MSCs are known to secrete various cytokines and molecules, which are secreted in response to environmental stimuli upon transplantation. These paracrine effects include anti-inflammatory, immune modulating, anti-tumor, and regenerative potentials, and many others [119] . Further researches on bioactive molecules secreted from stem cells will lead to the development of efficient and effective therapies without applying cell injection which is still on controversial issues. Collectively, therapeutic use of stem cells holds promising potentials due to their capability of replacing damaged tissue and exerting beneficial effects in a paracrine manner. Even though stem cell transplantation for liver failure is still on the stage of technology development, research progresses in this field are very rapid and active. Currently, optimizing experimental protocols for qualified stem cells would be the first priority. Unraveling the role of important paracrine factors responsible for curing liver failures needs to be explained in detail. In addition, larger clinical studies are essential to prove the clinical efficacy of stem cells. However, above all, it should be followed by understanding the molecular basis and underlying mechanism of liver regeneration to fully overcome and manage the liver failure.
